^
Association details:
| Biomarker: | MET expression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ST6GAL1 is a novel serum biomarker for lenvatinib-susceptible FGF19-driven hepatocellular carcinoma
Published date:
12/07/2020
Excerpt:
...lenvatinib and sorafenib, are used as standard-of-care chemotherapeutics in advanced HCC patients...sorafenib eliminated MET- and NRAS-expressing tumors...
DOI:
10.1158/1078-0432.CCR-20-3382
